RemeGen Co. Ltd. Class A
688331
Classement en actions
#2392
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces,... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Prix de l'action
$14.77
Capitalisation boursière
$8.27B
Changement (1 jour)
1.91%
Changement (1 an)
8.32%
Pays
CN
Échange RemeGen Co. Ltd. Class A (688331)
Catégorie
Healthcare
Revenus pour RemeGen Co. Ltd. Class A (688331)
Revenus en Jun 2026 TTM : $1.16B
Selon les derniers rapports financiers de RemeGen Co. Ltd. Class A, le chiffre d'affaires actuel de l'entreprise (TTM) est de $1.16B. En 2023, l'entreprise a réalisé un chiffre d'affaires de $152.99M une augmentation par rapport à le chiffre d'affaires de l'année 2022, qui était de $111.93M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour RemeGen Co. Ltd. Class A de 2018 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $1.16B | 393.27% |
| 2024 | $235.22M | 53.75% |
| 2023 | $152.99M | 36.68% |
| 2022 | $111.93M | -50.04% |
| 2021 | $224.03M | -301,419.47% |
| 2020 | $-74.35K | -119.31% |
| 2019 | $385.06K | -76.60% |
| 2018 | $1.65M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | 988.08% |
US
|
|
| $2.23B | 92.03% |
US
|
|
| $15.74B | 1,256.99% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 418.97% |
NL
|
